Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 8/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | GRK2 | P25098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32688097 | 0.77 | TOP2A (0.44) | CTSBTOP2ALMNAMAPTSCN9A | |
| SCHEMBL32688043 | 0.73 | LMNA (0.45) | LMNA | |
| SCHEMBL32688233 | 0.71 | CTSB (0.41) | CTSBTOP2A | |
| SCHEMBL32688156 | 0.71 | CTSB (0.47) | CTSBTOP2AMAPTSCN9ASMN1; SMN2 | |
| SCHEMBL32688025 | 0.70 | TOP2A (0.36) | CTSBTOP2A | |
| SCHEMBL32688367 | 0.70 | CTSB (0.39) | CTSBTOP2AMAPTDAO | |
| SCHEMBL32688382 | 0.69 | MEN1 (0.43) | CTSBLMNASMN1; SMN2 | |
| SCHEMBL32688260 | 0.68 | CTSB (0.42) | CTSBKDRTOP2AMAPTDAO | |
| SCHEMBL32688190 | 0.67 | CTSB (0.44) | CTSBEGFRTOP2AMAPT | |
| SCHEMBL5698030 | 0.63 | RAB9A (0.42) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | ORSOBIO INC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | CPT1B, CBR1, MUSK | CTSB 1942/4885RET 896/4885EGFR 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.